These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34438020)

  • 21. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
    Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
    Front Immunol; 2020; 11():188. PubMed ID: 32133000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
    Jagu S; Kwak K; Schiller JT; Lowy DR; Kleanthous H; Kalnin K; Wang C; Wang HK; Chow LT; Huh WK; Jaganathan KS; Chivukula SV; Roden RB
    J Virol; 2013 Jun; 87(11):6127-36. PubMed ID: 23536682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine.
    Azimi A; Heidarian S; Zamani H; Taleghani N; Dehghani M; Seyedjafari E
    Biologicals; 2020 Nov; 68():60-64. PubMed ID: 32859464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side.
    Shi L; Sings HL; Bryan JT; Wang B; Wang Y; Mach H; Kosinski M; Washabaugh MW; Sitrin R; Barr E
    Clin Pharmacol Ther; 2007 Feb; 81(2):259-64. PubMed ID: 17259949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
    Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
    Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
    Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus vaccine: widening the scope for cancer prevention.
    No JH; Kim MK; Jeon YT; Kim YB; Song YS
    Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8⁺ T cell responses and protective immunity.
    Santana VC; Diniz MO; Cariri FA; Ventura AM; Cunha-Neto E; Almeida RR; Campos MA; Lima GK; Ferreira LC
    PLoS One; 2013; 8(8):e71322. PubMed ID: 23951135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions.
    Le Tallec D; Doucet D; Elouahabi A; Harvengt P; Deschuyteneer M; Deschamps M
    Hum Vaccin; 2009 Jul; 5(7):467-74. PubMed ID: 19377291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
    Godi A; Bissett SL; Miller E; Beddows S
    J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles.
    Wang D; Liu X; Wei M; Qian C; Song S; Chen J; Wang Z; Xu Q; Yang Y; He M; Chi X; Huang S; Li T; Kong Z; Zheng Q; Yu H; Wang Y; Zhao Q; Zhang J; Xia N; Gu Y; Li S
    Nat Commun; 2020 Jun; 11(1):2841. PubMed ID: 32503989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.
    Senger T; Schädlich L; Textor S; Klein C; Michael KM; Buck CB; Gissmann L
    Vaccine; 2010 Feb; 28(6):1583-93. PubMed ID: 20003923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.